Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications

Giampaolo Tortora, Fortunato Ciardiello, Giampietro Gasparini

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Cellular heterogeneity, redundancy of molecular pathways and effects of the microenvironment contribute to the survival, motility and metastasis of cells in solid tumors. It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway; consequently, treatment with an agent that interferes with a single target may be insufficient. Combined blockade of functionally linked and relevant multiple targets has become an attractive therapeutic strategy. The EGFR and ERBB2 (HER2) pathways and VEGF-dependent angiogenesis have a pivotal role in cancer pathogenesis and progression. Robust experimental evidence has shown that these pathways are functionally linked and has demonstrated a suggested role for VEGF in the acquired resistance to anti-ERBB drugs when these receptors are pharmacologically blocked. Combined inhibition of ERBB and VEGF signaling interferes with a molecular feedback loop responsible for acquired resistance to anti-ERBB agents and promotes apoptosis while ablating tumor-induced angiogenesis. To this aim, either two agents highly selective against VEGF and ERBB respectively, or, alternatively, a single multitargeted agent, can be used. Preclinical studies have proven the efficacy of both these approaches and early clinical studies have provided encouraging results. This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling.

Original languageEnglish
Pages (from-to)521-530
Number of pages10
JournalNature Clinical Practice Oncology
Volume5
Issue number9
DOIs
Publication statusPublished - 2008

Fingerprint

Vascular Endothelial Growth Factor A
Neoplasms
Drug Receptors
Cell Movement
Clinical Studies
Clinical Trials
Apoptosis
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Combined targeting of EGFR-dependent and VEGF-dependent pathways : Rationale, preclinical studies and clinical applications. / Tortora, Giampaolo; Ciardiello, Fortunato; Gasparini, Giampietro.

In: Nature Clinical Practice Oncology, Vol. 5, No. 9, 2008, p. 521-530.

Research output: Contribution to journalArticle

Tortora, Giampaolo ; Ciardiello, Fortunato ; Gasparini, Giampietro. / Combined targeting of EGFR-dependent and VEGF-dependent pathways : Rationale, preclinical studies and clinical applications. In: Nature Clinical Practice Oncology. 2008 ; Vol. 5, No. 9. pp. 521-530.
@article{8165b443594943bf97b17c1658027df4,
title = "Combined targeting of EGFR-dependent and VEGF-dependent pathways: Rationale, preclinical studies and clinical applications",
abstract = "Cellular heterogeneity, redundancy of molecular pathways and effects of the microenvironment contribute to the survival, motility and metastasis of cells in solid tumors. It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway; consequently, treatment with an agent that interferes with a single target may be insufficient. Combined blockade of functionally linked and relevant multiple targets has become an attractive therapeutic strategy. The EGFR and ERBB2 (HER2) pathways and VEGF-dependent angiogenesis have a pivotal role in cancer pathogenesis and progression. Robust experimental evidence has shown that these pathways are functionally linked and has demonstrated a suggested role for VEGF in the acquired resistance to anti-ERBB drugs when these receptors are pharmacologically blocked. Combined inhibition of ERBB and VEGF signaling interferes with a molecular feedback loop responsible for acquired resistance to anti-ERBB agents and promotes apoptosis while ablating tumor-induced angiogenesis. To this aim, either two agents highly selective against VEGF and ERBB respectively, or, alternatively, a single multitargeted agent, can be used. Preclinical studies have proven the efficacy of both these approaches and early clinical studies have provided encouraging results. This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling.",
author = "Giampaolo Tortora and Fortunato Ciardiello and Giampietro Gasparini",
year = "2008",
doi = "10.1038/ncponc1161",
language = "English",
volume = "5",
pages = "521--530",
journal = "Nature Clinical Practice Oncology",
issn = "1743-4254",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Combined targeting of EGFR-dependent and VEGF-dependent pathways

T2 - Rationale, preclinical studies and clinical applications

AU - Tortora, Giampaolo

AU - Ciardiello, Fortunato

AU - Gasparini, Giampietro

PY - 2008

Y1 - 2008

N2 - Cellular heterogeneity, redundancy of molecular pathways and effects of the microenvironment contribute to the survival, motility and metastasis of cells in solid tumors. It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway; consequently, treatment with an agent that interferes with a single target may be insufficient. Combined blockade of functionally linked and relevant multiple targets has become an attractive therapeutic strategy. The EGFR and ERBB2 (HER2) pathways and VEGF-dependent angiogenesis have a pivotal role in cancer pathogenesis and progression. Robust experimental evidence has shown that these pathways are functionally linked and has demonstrated a suggested role for VEGF in the acquired resistance to anti-ERBB drugs when these receptors are pharmacologically blocked. Combined inhibition of ERBB and VEGF signaling interferes with a molecular feedback loop responsible for acquired resistance to anti-ERBB agents and promotes apoptosis while ablating tumor-induced angiogenesis. To this aim, either two agents highly selective against VEGF and ERBB respectively, or, alternatively, a single multitargeted agent, can be used. Preclinical studies have proven the efficacy of both these approaches and early clinical studies have provided encouraging results. This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling.

AB - Cellular heterogeneity, redundancy of molecular pathways and effects of the microenvironment contribute to the survival, motility and metastasis of cells in solid tumors. It is unlikely that tumors are entirely dependent on only one abnormally activated signaling pathway; consequently, treatment with an agent that interferes with a single target may be insufficient. Combined blockade of functionally linked and relevant multiple targets has become an attractive therapeutic strategy. The EGFR and ERBB2 (HER2) pathways and VEGF-dependent angiogenesis have a pivotal role in cancer pathogenesis and progression. Robust experimental evidence has shown that these pathways are functionally linked and has demonstrated a suggested role for VEGF in the acquired resistance to anti-ERBB drugs when these receptors are pharmacologically blocked. Combined inhibition of ERBB and VEGF signaling interferes with a molecular feedback loop responsible for acquired resistance to anti-ERBB agents and promotes apoptosis while ablating tumor-induced angiogenesis. To this aim, either two agents highly selective against VEGF and ERBB respectively, or, alternatively, a single multitargeted agent, can be used. Preclinical studies have proven the efficacy of both these approaches and early clinical studies have provided encouraging results. This Review discusses the experimental rationale for, preclinical studies of and clinical trials on combined blockade of ERBB and VEGF signaling.

UR - http://www.scopus.com/inward/record.url?scp=51149086367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51149086367&partnerID=8YFLogxK

U2 - 10.1038/ncponc1161

DO - 10.1038/ncponc1161

M3 - Article

C2 - 18594498

AN - SCOPUS:51149086367

VL - 5

SP - 521

EP - 530

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1743-4254

IS - 9

ER -